Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · Jan 29, 2024

Keywords

ClinConnect Summary

The SBAMOL study is a clinical trial focused on small bowel adenocarcinoma, a rare type of cancer that affects the small intestine. The main goal of this study is to find specific biological markers that can help doctors understand the disease better and create personalized treatment plans for patients. This is important because there is still a lot we don’t know about the best ways to manage this cancer.

If you are at least 18 years old and have been diagnosed with small bowel adenocarcinoma, you might be eligible to participate in this trial. However, if there isn’t enough tissue available for testing or if you have opted out of allowing your biological material to be used for research, you won't be able to join. As a participant, you can expect to provide samples for testing, which will help researchers learn more about the disease and how to treat it effectively. Your involvement could contribute to advancements in personalized care for this rare cancer, benefiting future patients.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years
• Exclusion criteria:
• • Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\&
• • Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.